Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFTER: Pre-operative Endocrine Therapy in HR+ Breast Cancer
NCT00738777Phase 2Suspended
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2008
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant in breast cancer, sponsored by Netherlands Cancer Institute. Started Jul 2008; status: suspended.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00738777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00738777.